FFTT

3.0002.56%

‘Get Ready for What’s Next,’ Says Morgan Stanley About Rocket Lab Stock

LongbridgeAII'm LongbridgeAI. Here is the key information I extracted
- Morgan Stanley maintains an overweight rating on Rocket Lab with a 103 USD price target, driven by strong third-quarter financial results and a growing backlog of 3,570,000,000 USD.
- The company reported 267,800,000 USD in third-quarter revenue, representing a 73 percent year-over-year increase, alongside a new 515,000,000 USD Neutron launch contract.…
Disclaimer

Rocket Lab (NASDAQ:RKLB) is extending its winning streak on Wednesday, with shares climbing nearly 7% and bringing their four-day gains to 44%. The remarkable comeback follows the space company’s latest earnings release, which gave investors several reasons to look beyond near-term challenges surrounding its next-generation Neutron rocket.

The company reported third-quarter revenue of $267.8 million, representing 73% annual growth, while its order backlog jumped 52% to $3.57 billion. Investors also found encouragement in $515 million worth of new Neutron launch contracts, suggesting customers remain willing to make sizable commitments despite the rocket’s inaugural flight being delayed until 2027.

Morgan Stanley analyst Kristine Liwag believes there is more upside ahead, assigning RKLB an Overweight (i.e., Buy) rating alongside a $103 price target that implies about 54% upside from current levels. (To watch Liwag’s track record, click here)

Liwag believes investors focusing on the company’s near-term challenges are overlooking its long-term growth potential. The analyst sees a promising future for Neutron, whose improving commercial prospects could eventually transform Rocket Lab’s financial performance.

Several new contracts now command about $70 million per mission, compared with the $50 million to $55 million previously assumed in Liwag’s forecasts. These higher rates have prompted the analyst to raise her estimated average selling price for 2030 to $66 million, up from $55.5 million.

However, investors will need patience before those improved terms translate into financial results. Rocket Lab anticipates conducting one Neutron flight in 2027, three during 2028, and five the following year. Since earlier agreements were negotiated at lower prices, the latest bookings should contribute most heavily toward the decade’s end.

Liwag also believes greater launch frequency could improve profitability as Rocket Lab spreads operating expenses over additional missions. Reusing rocket components should provide another advantage, potentially helping the program achieve its long-term non-GAAP gross margin goal of more than 50%.

Meanwhile, existing operations continue supporting the company’s expansion beyond its upcoming medium-lift rocket. Recent agreements include 20 Electron missions for Japanese satellite operator Synspective and 18 HASTE launches for the U.S. Space Force. Rocket Lab also has more than 55 spacecraft in development or production, providing another source of future revenue.

Still, Liwag recognizes several financial challenges that investors should keep in mind. Third-quarter operating cash flow benefited from a $70 million satellite milestone payment that isn’t expected to recur regularly. Neutron development expenses will remain elevated, while financing for the pending Iridium acquisition has increased the total share count. Importantly, Liwag’s valuation already incorporates the additional equity issuance without accounting for any potential earnings contribution from Iridium.

Looking further ahead, Liwag now forecasts $3.11 billion in revenue and $943 million in adjusted EBITDA for 2030. Those projections suggest Rocket Lab could become far more profitable as Neutron begins generating income from higher-priced missions.

Liwag’s bullish outlook is shared by most of Wall Street, with 15 Buy recommendations and 3 Holds giving Rocket Lab a Strong Buy consensus rating. The average 12-month price target of $95.35 suggests about 42% upside from current levels. (See RKLB stock forecast)

Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment decision.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.